FR3099053B1 - Souches bacteriennes pour le traitement et la prevention d’une inflammation gastro-intestinale - Google Patents

Souches bacteriennes pour le traitement et la prevention d’une inflammation gastro-intestinale Download PDF

Info

Publication number
FR3099053B1
FR3099053B1 FR1908385A FR1908385A FR3099053B1 FR 3099053 B1 FR3099053 B1 FR 3099053B1 FR 1908385 A FR1908385 A FR 1908385A FR 1908385 A FR1908385 A FR 1908385A FR 3099053 B1 FR3099053 B1 FR 3099053B1
Authority
FR
France
Prior art keywords
prevention
treatment
bacterial strain
bacterial strains
christensenella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1908385A
Other languages
English (en)
Other versions
FR3099053A1 (fr
Inventor
Philippe Langella
Patrizia Brigidi
Rosique Rebeca Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de Recherche pour lAgriculture lAlimentation et lEnvironnement
Original Assignee
Institut National de la Recherche Agronomique INRA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Recherche Agronomique INRA filed Critical Institut National de la Recherche Agronomique INRA
Priority to FR1908385A priority Critical patent/FR3099053B1/fr
Priority to PCT/EP2020/070830 priority patent/WO2021013944A1/fr
Priority to US17/629,149 priority patent/US20220339207A1/en
Priority to EP20742750.1A priority patent/EP4003380A1/fr
Priority to CA3145274A priority patent/CA3145274A1/fr
Publication of FR3099053A1 publication Critical patent/FR3099053A1/fr
Application granted granted Critical
Publication of FR3099053B1 publication Critical patent/FR3099053B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Souches bactériennes pour le traitement et la prévention d’une inflammation gastro-intestinale La présente invention concerne une composition pour son utilisation dans le traitement et/ou la prévention d’une maladie gastro-intestinale inflammatoire chez un individu, la composition comprenant, dans un milieu physiologiquement acceptable, au moins (I) (a) une première souche bactérienne de l’espèce Faecalibacterium prausnitzii, et/ou (b) un surnageant de culture d’une première souche bactérienne de l’espèce Faecalibacterium prausnitzii ; et (II) (a) une seconde souche bactérienne choisie dans le groupe constitué de Christensenella minuta, Christensenella timonensis et leurs mélanges, et/ou (b) un surnageant de culture d’une seconde souche bactérienne choisie dans le groupe constitué de Christensenella minuta, Christensenella timonensis et leurs mélanges.
FR1908385A 2019-07-24 2019-07-24 Souches bacteriennes pour le traitement et la prevention d’une inflammation gastro-intestinale Active FR3099053B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR1908385A FR3099053B1 (fr) 2019-07-24 2019-07-24 Souches bacteriennes pour le traitement et la prevention d’une inflammation gastro-intestinale
PCT/EP2020/070830 WO2021013944A1 (fr) 2019-07-24 2020-07-23 Souches bacteriennes de faecalibacterium prausnitzii et de christensenella pour le traitement et la prevention d'une inflammation gastro-intestinale
US17/629,149 US20220339207A1 (en) 2019-07-24 2020-07-23 Faecalibacterium prausnitzii and christensenella bacterial strains for the treatment and prevention of bowel inflammation
EP20742750.1A EP4003380A1 (fr) 2019-07-24 2020-07-23 Souches bacteriennes de faecalibacterium prausnitzii et de christensenella pour le traitement et la prevention d'une inflammation gastro-intestinale
CA3145274A CA3145274A1 (fr) 2019-07-24 2020-07-23 Souches bacteriennes de faecalibacterium prausnitzii et de christensenella pour le traitement et la prevention d'une inflammation gastro-intestinale

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1908385 2019-07-24
FR1908385A FR3099053B1 (fr) 2019-07-24 2019-07-24 Souches bacteriennes pour le traitement et la prevention d’une inflammation gastro-intestinale

Publications (2)

Publication Number Publication Date
FR3099053A1 FR3099053A1 (fr) 2021-01-29
FR3099053B1 true FR3099053B1 (fr) 2023-01-20

Family

ID=68806966

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1908385A Active FR3099053B1 (fr) 2019-07-24 2019-07-24 Souches bacteriennes pour le traitement et la prevention d’une inflammation gastro-intestinale

Country Status (5)

Country Link
US (1) US20220339207A1 (fr)
EP (1) EP4003380A1 (fr)
CA (1) CA3145274A1 (fr)
FR (1) FR3099053B1 (fr)
WO (1) WO2021013944A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113069475B (zh) * 2021-04-06 2023-06-02 慕恩（广州）生物科技有限公司 一种细菌菌株及组合物和用途
US20240226030A1 (en) * 2021-05-06 2024-07-11 Société des Produits NESTLE S.A. Compositions and methods using at least one of inositol, erythritol or sorbitol to enhance growth of faecalibacterium prausnitzii
CN114259507B (zh) * 2021-12-27 2022-09-16 暨南大学 一种小克里斯滕森氏菌在制备治疗和/或预防高尿酸相关疾病的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016156527A1 (fr) 2015-03-31 2016-10-06 International Nutrition Research Company Composition pour le traitement d'un etat metabolique pathogene du microbiote intestinal et des maladies derivees
FR3046934B1 (fr) * 2016-01-25 2018-01-26 Institut National De La Recherche Agronomique (Inra) Souche de faecalibacterium prausnitzii cncm i-4573 pour le traitement et la prevention d'une inflammation gastro-intestinale
FR3063646B1 (fr) 2017-03-10 2021-07-30 International Nutrition Res Company Bacteries specifiques pour leur utilisation comme medicament en particulier pour lutter contre le surpoids, l'obesite, les maladies cardiometaboliques et les maladies inflammatoires de l'intestin

Also Published As

Publication number Publication date
FR3099053A1 (fr) 2021-01-29
WO2021013944A1 (fr) 2021-01-28
CA3145274A1 (fr) 2021-01-28
US20220339207A1 (en) 2022-10-27
EP4003380A1 (fr) 2022-06-01

Similar Documents

Publication Publication Date Title
FR3099053B1 (fr) Souches bacteriennes pour le traitement et la prevention d’une inflammation gastro-intestinale
Lamont et al. The oral microbiota: dynamic communities and host interactions
Marsh et al. Dental biofilm: ecological interactions in health and disease
Marx et al. The mesenchymal stromal cell secretome impairs methicillin-resistant Staphylococcus aureus biofilms via cysteine protease activity in the equine model
Kovachev Defence factors of vaginal lactobacilli
Salvatori et al. Innate immunity and saliva in Candida albicans–mediated oral diseases
Cattoir et al. Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce?
Schuch et al. Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus–induced murine bacteremia
Van Hal et al. Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns
MA41759A (fr) Inclusion de l'exon 2, induite par antisens, dans une alpha-glucosidase acide
MA50949B1 (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
Horz et al. Diagnosis and anti-infective therapy of periodontitis
FR2992973A1 (fr) Nouvelle souche de lactobacillus crispatus
MA44593A1 (fr) Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
AU2011206532A8 (en) Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)
Beltrame et al. Inactivation of the autolysis-related genes lrgB and yycI in Staphylococcus aureus increases cell lysis-dependent eDNA release and enhances biofilm development in vitro and in vivo
MA34097B1 (fr) Utilisations d'inhibiteurs de dgat1
EP4242295A3 (fr) Souche de b. amyloliquefaciens et utilisation thérapeutique
Liu et al. Knockdown of GRP78 promotes apoptosis in pancreatic acinar cells and attenuates the severity of cerulein and LPS induced pancreatic inflammation
Damé-Teixeira et al. Gene expression of bacterial collagenolytic proteases in root caries
Alshanta et al. Candida albicans and Enterococcus faecalis biofilm frenemies: When the relationship sours
EP4373064A8 (fr) Techniques de décision d'appariement comportemental dans un système d'attribution de tâches
NO20052956D0 (no) Defensinprotiner
Marttila et al. Intracellular localization of Treponema denticola chymotrypsin-like proteinase in chronic periodontitis
Dhandapani et al. Proteomic approach and expression analysis revealed the differential expression of predicted leptospiral proteases capable of ECM degradation

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210129

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

CD Change of name or company name

Owner name: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULT, FR

Effective date: 20220718

PLFP Fee payment

Year of fee payment: 5